Quinones C A, Reuben A G, Hamill R J, Musher D M, Gorin A B, Sarosi G A
Division of General Internal Medicine, University of Texas Health Science Center, Houston.
Chest. 1989 Apr;95(4):914-6. doi: 10.1378/chest.95.4.914.
Ketoconazole appears to be a safe drug in the treatment of chronic cavitary histoplasmosis. Primary failure and relapse have been described, requiring amphotericin B, even after long therapy with ketoconazole. Four typical cases are presented. We caution about such potential failures and stress the importance of close observation of patients begun on therapy with ketoconazole for chronic cavitary histoplasmosis.
酮康唑在治疗慢性空洞型组织胞浆菌病方面似乎是一种安全的药物。已有原发性治疗失败和复发的报道,即便在长期使用酮康唑治疗后,仍需要使用两性霉素B。本文介绍了4个典型病例。我们对这种潜在的治疗失败情况提出警示,并强调对于开始使用酮康唑治疗慢性空洞型组织胞浆菌病的患者进行密切观察的重要性。